MAPT and early-onset autosomal dominant Alzheimer disease: In the literature, the focus of iPSC-derived-exosomes therapy is Alzheimer’s disease (AD); the defining hallmarks of AD are the progressive accumulation of amyloid-β (Aβ) and hyperphosphorylated tau proteins [73, 74].